CD19 Knockout Raji/Luciferase Cell Line

Description

CD19 Knockout Raji/Luciferase Cell Line is a genetically engineered B-lymphocyte model derived from Raji cells, featuring dual modifications: stable integration of luciferase (Luc) reporter gene and complete knockout of CD19 expression. This cell line maintains characteristic Raji cell morphology and growth properties while providing sensitive bioluminescence detection for in vivo tumor tracking. The CD19 knockout eliminates target expression for CD19-directed immunotherapies (including CAR-T cells and monoclonal antibodies), making it particularly valuable for studying therapy resistance mechanisms and developing alternative treatment strategies for B-cell malignancies. Cells exhibit stable luciferase expression across passages (<P20) with consistent proliferation rates, enabling reliable longitudinal studies in xenograft models. The cell line is rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, Fungi, Yeast and Bacteria.